About: Dose tapering for ciclosporin in cats with nonflea‐induced hypersensitivity dermatitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dose tapering for ciclosporin in cats with nonflea‐induced hypersensitivity dermatitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dose tapering for ciclosporin in cats with nonflea‐induced hypersensitivity dermatitis
Creator	Cannon, Andrea Fontaine, Jacques Forsythe, Peter King, Stephen Pr Elaud §, Pascal Roberts, Elizabeth Seewald, Wolfgang Steffan, Jean
Source	Medline; PMC
abstract	BACKGROUND: Little information is available on the ciclosporin dose‐tapering regimen and clinical response in the treatment of feline hypersensitivity dermatitis. HYPOTHESIS/OBJECTIVES: To test a dose‐tapering regimen and assess efficacy and clinical safety for up to 18 weeks. ANIMALS: Eighty‐eight client‐owned cats with feline hypersensitivity dermatitis. METHODS: Cats that received either a placebo or ciclosporin at 2.5 mg/kg or 7 mg/kg daily for 6 weeks were given 7 mg/kg ciclosporin daily for 4 weeks. Depending on the clinical response, the dose was tapered from daily to every other day over the next 4 weeks and further to twice a week for an additional 4 weeks. RESULTS: After all cats received 7 mg/kg for 4 weeks, the dose could be tapered to every other day for the next 4 weeks in 70% of cats remaining in the study. During the next 4 weeks, 57, 15 and 22% of cats remaining in the study could be treated at twice a week, every other day or daily, respectively. After the first 4 weeks, the mean lesion score and owner‐assessed pruritus improved over baseline by 69 and 61%, respectively, and remained stable during the following 8 weeks. Approximately 65% of the cats in the study were reported to have an adverse event (AE), very often mild and resolving spontaneously. The most frequent AEs were gastrointestinal and included primarily vomiting and diarrhoea. Eighty per cent of AEs occurred when cats were on daily treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that the induction dose of 7 mg/kg ciclosporin can be tapered as soon as 4 weeks without deterioration of the clinical response. Establishment of the lowest effective dosing regimen of ciclosporin reduced the frequency of AEs.
has issue date	2013-03-27(xsd:dateTime)
bibo:doi	10.1111/vde.12018
bibo:pmid	23530522
has license	no-cc
sha1sum (hex)	60660ced1fb008a0fa92152b36b171e8073706ed
schema:url	https://doi.org/10.1111/vde.12018
resource representing a document's title	Dose tapering for ciclosporin in cats with nonflea‐induced hypersensitivity dermatitis
has PubMed Central identifier	PMC7169265
has PubMed identifier	23530522
schema:publication	Vet Dermatol
resource representing a document's body	covid:60660ced1fb008a0fa92152b36b171e8073706ed#body_text
is schema:about of	named entity 'hypersensitivity' named entity 'hypersensitivity' named entity 'ciclosporin' named entity 'ciclosporin' named entity 'body weight' named entity 'body weight' named entity 'ciclosporin' named entity 'organ' named entity 'Vercelli' named entity 'fungal infections' named entity 'ciclosporin' named entity 'Toxoplasma gondii' named entity 'serology' named entity 'OPS' named entity 'pruritus' named entity 'SAS' named entity 'Phases 1' named entity '10.4' named entity 'therapeutic effects' named entity 'hypersensitivity' named entity 'alopecia' named entity 'Phase 1' named entity 'Phase 2' named entity 'weight loss' named entity 'pruritus' named entity 'Cary, NC' named entity 'effective dose' named entity 'Ciclosporin' named entity 'systemic disease' named entity 'phase 1' named entity 'Elizabethan collar' named entity 'weight loss' named entity 'selamectin' named entity 'lesion' named entity 'ciclosporin' named entity 'pruritus' named entity 'MDR1' named entity 'puede ser' named entity 'Phase 2' named entity 'systemic infection' named entity 'toxoplasmosis' named entity 'Phase 1' named entity 'Phase 1' named entity 'ciclosporin' named entity 'vomiting' named entity 'amitriptyline' named entity 'dermatitis' named entity 'placebo control' named entity '19, 20' named entity 'dermatitis' named entity 'Haematology' named entity 'lesion' named entity 'alopecia' named entity 'vomiting' named entity 'Phase 1' named entity 'ciclosporin' named entity 'creatinine' named entity 'weight loss' named entity 'Pruritus' named entity 'Phase 1' named entity 'ciclosporin' named entity 'kg 6' named entity 'lethargy' named entity 'ciclosporin' named entity 'dermatitis' named entity 'hyperthyroidism' named entity 'biochemistry' named entity 'erythromycin' named entity 'Phase 2' named entity 'hypersensitivity' named entity 'body weight' named entity 'ciclosporin' named entity 'allergy' named entity 'ciclosporin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software